APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Sponsor
Sun Yat-sen University
Study ID
NCT03164694
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib was given 850 mg per day orally.
  • Pemetrexed — DRUG
    pemetrexed (500 mg/m2)
  • Carboplatin — DRUG
    carboplatin (AUC =5)

Study Details

The purpose of this study is to studying the addition of apatinib with chemotherapy to investigate the efficacy and safety of apatinib in combination with chemotherapy in patients with advanced NSCLC.

Key Dates

Start date
May 20, 2017
Status verified
Dec 2024
Primary completion
May 20, 2025
Completion
May 20, 2027

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
  • Active Comparator: Control
    Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).

Primary Outcome Measure

Overall survival [ Time Frame: 1 year after the last patient is randomized ]

Related Studies